Department of Pharmacology, Universidad de Alcalá, Crta Madrid-Zaragoza Km 33.6, Alcalá de Henares, Spain.
Drug Discov Today. 2019 Jun;24(6):1304-1310. doi: 10.1016/j.drudis.2019.04.005. Epub 2019 Apr 10.
Malaria affects a population of over 200 million people worldwide. New drugs are needed because of widespread resistance, and the hunt for such drugs involves a coordinated research effort from the scientific community. The release of the Tres Cantos Antimalarial Set (TCAMS) in 2010 represented a landmark in the field of collaborative drug discovery for malaria. This set of >13 000 molecules with confirmed activity against several strains of Plasmodium falciparum was publicly released with the goal of fostering additional research beyond the GlaxoSmithKline (GSK) network of collaborators. Here, we examine the outcomes realized from TCAMS over the past 8 years and whether the expectations surrounding this initiative have become a reality.
疟疾影响着全球超过 2 亿人的生命。由于广泛的抗药性，我们需要新的药物，科学界正在进行协调一致的研究来寻找这些药物。2010 年 Tres Cantos 抗疟药物集（TCAMS）的发布是疟疾合作药物发现领域的一个里程碑。该药物集包含超过 13000 种对多种疟原虫株具有确认活性的分子，并公开发布，旨在促进除葛兰素史克（GSK）合作网络之外的更多研究。在这里，我们研究了过去 8 年来 TCAMS 取得的成果，以及围绕这一举措的预期是否已经成为现实。
